NCT02053116View on ClinicalTrials.gov

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

PF-05175157

Tablet, 200 mg, twice daily, 6 weeks

DRUG

Placebo

Tablet, 0 mg, twice daily, 2 weeks

Trial Locations (1)

32720

Pfizer Investigational Site, DeLand

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02053116 - A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin | Biotech Hunter | Biotech Hunter